Purple Biotech (1YI) Price & Analysis

Compare

0 Followers

1YI Stock Chart & Stats

€0.28

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.28

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.28 - €0.38

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€6.40M

Enterprise Value€644.36K

Total Cash (Recent Filing)€5.92M

Total Debt (Recent Filing)€103.00K

Price to Earnings (P/E)―

Beta-0.44

Next Earnings

Nov 11, 2025

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding9,292,398

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Biomarker AnalysisVarious biomarker analysis on the Phase 2 CM24 trial demonstrates improved overall survival.

Efficacy Of CM24The CM24 experimental arm had consistently greater efficacy for every evaluated endpoint.

Bears Say

Imbalance In Clinical TrialThe CM24 + nivolumab + gem/nab-paclitaxel cohort was impacted by informative censoring of the control arm which led to an imbalance in the number of patients in the active and control arms.

Purple Biotech News

3 Penny Stocks to Watch Now, 10/30/25

Cambium Networks, Purple Biotech, and Ernexa Therapeutics are the 3 Penny Stocks to watch on October 30, 2025, based on TipRanks’...

7d ago

CMBM

ERNA

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Traders have loads of stock market news to read on Wednesday as earnings and other topics dominate today’s headlines. ...

8d ago

Why Is Purple Biotech Stock (PPBT) Up 95% Today?

Purple Biotech stock gained on Wednesday after the company reached a production milestone. ...

8d ago

PPBT

Purple Biotech achieves manufacturing milestone for IM1240

Purple Biotech (PPBT) announced the achievement of a manufacturing milestone for IM1240, a tri-specific antibody from the CAPTN-3...

8d ago

PPBT

Purple Biotech receives noncompliance notification from Nasdaq

Purple Biotech (PPBT) announced that it received a letter from the listings qualifications department of Nasdaq notifying the...

17d ago

PPBT

Purple Biotech Reaches Manufacturing Milestone for IM1240 Antibody

Purple Biotech ( ($PPBT) ) has shared an announcement. On October 29, 2025, Purple Biotech announced a significant...

8d ago

PPBT

Purple Biotech Announces Extraordinary General Meeting for December 2025

Purple Biotech ( ($PPBT) ) has provided an update. On October 28, 2025, Purple Biotech Ltd. announced an...

9d ago

PPBT

Purple Biotech Receives Nasdaq Bid Price Notification

Purple Biotech ( ($PPBT) ) just unveiled an update. On October 16, 2025, Purple Biotech received a notification...

17d ago

PPBT

Purple Biotech Enters New ATM Agreement with H.C. Wainwright

The latest announcement is out from Purple Biotech ( ($PPBT) ). On September 19, 2025, Purple Biotech Ltd....

2M ago

PPBT

Purple Biotech Unveils Promising Cancer Treatment Developments in September 2025 Update

Purple Biotech ( ($PPBT) ) has issued an update. On September 15, 2025, Purple Biotech Ltd. released an...

2M ago

PPBT

Purple Biotech Secures European Patent for NT219 Combinations

An update from Purple Biotech ( ($PPBT) ) is now available. On September 10, 2025, Purple Biotech announced...

2M ago

PPBT

Purple Biotech receives intention to grant a European patent covering NT219

Purple Biotech (PPBT) announced that the Examining Division of the European Patent Office has issued an intention to...

2M ago

PPBT

Purple Biotech Announces $18 Million Public Offering to Boost Oncology Pipeline

Purple Biotech ( ($PPBT) ) just unveiled an announcement. On September 4, 2025, Purple Biotech announced the pricing...

2M ago

PPBT

Purple Biotech prices 5.99M ADSs at $1.00 in public offering

Purple Biotech (PPBT) announced the pricing of a public offering of an aggregate of 5,999,999 of the Company’s...

2M ago

PPBT

1YI FAQ

What was Purple Biotech Ltd.’s price range in the past 12 months?

Purple Biotech Ltd. lowest stock price was €0.28 and its highest was €0.38 in the past 12 months.

What is Purple Biotech Ltd.’s market cap?

Purple Biotech Ltd.’s market cap is €6.40M.

When is Purple Biotech Ltd.’s upcoming earnings report date?

Purple Biotech Ltd.’s upcoming earnings report date is Nov 11, 2025 which is in 5 days.

How were Purple Biotech Ltd.’s earnings last quarter?

Purple Biotech Ltd. released its earnings results on Aug 06, 2025. The company reported -€0.343 earnings per share for the quarter, missing the consensus estimate of -€0.18 by -€0.163.

Is Purple Biotech Ltd. overvalued?

According to Wall Street analysts Purple Biotech Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Purple Biotech Ltd. pay dividends?

Purple Biotech Ltd. does not currently pay dividends.

What is Purple Biotech Ltd.’s EPS estimate?

Purple Biotech Ltd.’s EPS estimate is -0.22.

How many shares outstanding does Purple Biotech Ltd. have?

Purple Biotech Ltd. has 9,292,398 shares outstanding.

What happened to Purple Biotech Ltd.’s price movement after its last earnings report?

Purple Biotech Ltd. reported an EPS of -€0.343 in its last earnings report, missing expectations of -€0.18. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Purple Biotech Ltd.?

Currently, no hedge funds are holding shares in DE:1YI

Company Description

Purple Biotech Ltd.

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.